CervoMed Inc. CRVO 深 滬
已收盤 08-07 16:00:00 美东时间
2.87
+0.110
+3.99%
華盛通- 最 高2.88
- 今 開2.84
- 成交量 19.44万股
- 最 低 2.78
- 昨 收 2.76
- 總市值 3882.03万
- 52周最高 11.25
- 市盈率 靜 --
- 換手率 1.44%
- 52周最低 2.13
- 委 比 -84.33%
- 總股本 1352.62万
- 歷史最高 17437.50
- 量 比 0.50
- 振 幅 3.62%
- 歷史最低 1.80
- 每 手 1
- 風險率 2.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
CervoMed's neflamapimod granted Innovation Passport for UK's ILAP program to accelerate development for DLB, a common dementia with limited treatment options. The program offers coordinated guidance from UK regulators and NHS to expedite patient access. Neflamapimod targets neuroinflammation and has shown promise in early trials.
08-04 09:15
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
CervoMed Completes Enrollment in Phase 2a Neflamapimod Trial
CervoMed ( ($CRVO) ) has issued an update. On July 9, 2026, CervoMed Inc., a cl...
07-10 04:29
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
CervoMed Inc. will present five studies on neflamapimod, its oral drug candidate for dementia with Lewy bodies (DLB), at the AAIC meeting in London. The studies highlight neflamapimod's potential to slow DLB progression, reduce biomarkers of neurodegeneration, and improve basal forebrain atrophy. Neflamapimod, a p38α kinase inhibitor, has shown promising results in Phase 2 trials, including improved cognitive and functional outcomes. CervoMed is ...
07-06 11:30
CervoMed Raises $10 Million in Direct Offering
CervoMed ( ($CRVO) ) just unveiled an update. On June 22, 2026, CervoMed Inc. c...
06-23 04:30
CervoMed Receives U.S. Patent For Its Neflamapimod Drug Candidate For The Treatment Of Dementia With Lewy Bodies
CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecti...
06-18 19:07
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
CervoMed Inc. has received a patent allowance from the USPTO for its drug candidate, neflamapimod, targeting the treatment of pure dementia with Lewy bodies (DLB) without substantial Alzheimer’s disease-like tau pathology. The patent, valid until 2042, aims to protect the company's strategy for treating pure DLB, a condition with no approved therapies in the US or EU. CervoMed is advancing neflamapimod through clinical trials, with a Phase 3 tria...
06-18 11:00
美股夜盘 | Micropolis Holding Co.涨54.33%，金生游乐涨35.00%
CervoMed Inc.涨-14.16%；Nexentis Technologies Inc.涨-13.40%；Neumora Therapeutic涨-9.62%
06-17 08:05
美股夜盘 | SpaceX涨超4%，SpaceX称承销商已行使绿鞋期权，IPO总募资额增至857亿美元
SpaceX涨超4%，SpaceX称承销商已行使绿鞋期权，IPO总募资额增至857亿美元；CervoMed飙涨近40%，HIGH TIDE涨14.67%，爱奇艺涨2.86%>>
06-16 08:05
